10.6084/M9.FIGSHARE.21582452
Andrea Anichini
Andrea
Anichini
0000-0001-5096-5538
Fondazione IRCCS Istituto Nazionale dei Tumori
Alessandra Molla
Alessandra
Molla
Fondazione IRCCS Istituto Nazionale dei Tumori
Gabriella Nicolini
Gabriella
Nicolini
Fondazione IRCCS Istituto Nazionale dei Tumori
Valentina Eleonora Perotti
Valentina Eleonora
Perotti
Fondazione IRCCS Istituto Nazionale dei Tumori
Francesco Sgambelluri
Francesco
Sgambelluri
Fondazione IRCCS Istituto Nazionale dei Tumori
Alessia Covre
Alessia
Covre
Azienda Ospedaliera Universitaria Senese
University of Siena
Carolina Fazio
Carolina
Fazio
Azienda Ospedaliera Universitaria Senese
Maria Fortunata Lofiego
Maria Fortunata
Lofiego
Azienda Ospedaliera Universitaria Senese
Anna Maria Di Giacomo
Anna Maria
Di Giacomo
Azienda Ospedaliera Universitaria Senese
University of Siena
Sandra Coral
Sandra
Coral
Azienda Ospedaliera Universitaria Senese
Antonella Manca
Antonella
Manca
National Research Council
Maria Cristina Sini
Maria Cristina
Sini
National Research Council
Marina Pisano
Marina
Pisano
National Research Council
Teresa Noviello
Teresa
Noviello
Biogem
University of Naples Federico II
Francesca Caruso
Francesca
Caruso
Biogem
University of Naples Federico II
Silvia Brich
Silvia
Brich
Fondazione IRCCS Istituto Nazionale dei Tumori
Giancarlo Pruneri
Giancarlo
Pruneri
Fondazione IRCCS Istituto Nazionale dei Tumori
University of Milan
Andrea Maurichi
Andrea
Maurichi
Fondazione IRCCS Istituto Nazionale dei Tumori
Mario Santinami
Mario
Santinami
Fondazione IRCCS Istituto Nazionale dei Tumori
Michele Ceccarelli
Michele
Ceccarelli
Biogem
University of Naples Federico II
Giuseppe Palmieri
Giuseppe
Palmieri
University of Sassari
National Research Council
Michele Maio
Michele
Maio
Azienda Ospedaliera Universitaria Senese
University of Siena
Roberta Mortarini
Roberta
Mortarini
Fondazione IRCCS Istituto Nazionale dei Tumori
Additional file 2 of Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy
Additional file 2: Supplementary Figs. S1 to S21. Supplementary Fig. S1. Expression in ten melanoma cell lines of genes and gene families targeted by epigenetic drugs. Supplementary Fig. S2. Differentiation profile of melanoma cell lines. Supplementary Fig. S3. Susceptibility of ten melanoma cell lines to the anti-proliferative effects of epigenetic drugs. Supplementary Fig. S4. Methylation status of LINE-1, MAGE-A1 and NY-ESO-1 in 9 melanoma cell lines treated with guadecitabine. Supplementary Fig. S5. Volcano plot of differentially expressed genes in VRG100 and CST30 cell lines. Supplementary FigureS6. Whole genome gene modulation analysis by 4 epigenetic drugs in two melanoma cell lines. Supplementary Fig. S7. Edwards-VENN diagram analysis of significantly modulated genes by epigenetic drugs. Supplementary Fig. S8. Original and revised gene classification of the NanoString nCounter PanCancer Immune Profiling panel. Supplementary Fig. S9. Quantitative analysis of Nanostring data in ten melanoma cell lines treated with epigenetic drugs. Supplementary Fig. S10. Modulation of immune-related genes in melanoma cell lines by epigenetic drugs. Supplementary Fig. S11. Comparison of immune-related gene modulation by BET inhibitors JQ1 and OTX-015. Supplementary Fig. S12. Immune-related signature of epigenetic drugs in melanoma. Supplementary Fig. S13. Outline of the strategy for quantitative analysis and visualization of western blot data. Supplementary Fig. S14. Quantitative western blot analysis and visualization of the modulation of LMP7 by epigenetic drugs in 11 melanoma cell lines. Supplementary Fig. S15. Pipeline of data analysis based on Upstream Regulators (UR) identified by IPA. Supplementary Fig. S16. Classification of URs significantly modulated by at least two different drugs in melanoma cell line VRG100. Supplementary Fig. S17. Classification of URs significantly modulated by at least two different drugs in melanoma cell line CST30. Supplementary Fig. S18. Summary of the major functional networks linking relevant URs emerging from IPA Core Analysis in melanoma cell line VRG100. Supplementary Fig. S19. Comparison of URs activated by guadecitabine in-vitro and in-vivo. Supplementary Fig. S20. Comparison of URs activated by guadecitabine in melanoma cell line VRG100 vs a mesothelioma cell line vs hepatocarcinoma cell lines. Supplementary Fig. S21. Prognostic significance of selected genes in the guadecitabine signatures in 41 TCGA tumor types.
Genetics
figshare
2022
2022-11-18
2022-11-18
Journal contribution
6275374 Bytes
10.1186/s13046-022-02529-5
CC BY + CC0